PRIVISCL Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Privi Speciality Chemicals reported its strongest ever quarterly performance with record revenue of INR773.16 crores (up 13.9% YoY) and EBITDA of INR212.49 crores (up 16.66% YoY), PAT of INR117.03 crores (up 24.61% YoY). Management declared first interim dividend of INR5/share. Phase 1 capacity expansion completed (48,000 to 54,000 MTPA), with volume ramp-up expected in Q4 FY27. Company maintains 20% growth guidance and expects to maintain EBITDA margins. Phase 2 and 3 expansions on track for ~INR1,900 crores revenue by 2030. Balance sheet strong with ROCE 24.30%, net debt/EBITDA 1.07x, working capital cycle below 100 days. Key risks include geopolitical uncertainty and input cost volatility.
Management Tone
- Prepared Remarks: Great — Management highlighted the strongest ever quarterly performance, first interim dividend, capacity expansion completion, and confident outlook for 20% growth and maintaining margins.
- Q&A Session: Good — Analysts asked about capacity ramp-up, growth guidance, margins, capex, and JV performance. Management provided direct answers on most topics, though some responses on customer contracts and new partnerships were guarded. Tone remained constructive.
Revenue Growth Drivers
- Broad-based demand across domestic and export markets
- Capacity expansion Phase 1 completed, volume ramp-up expected in Q4 FY27
- New contracts and newer products
Growth vs Margin Focus
Management emphasized 20% revenue growth and maintaining EBITDA margins, with focus on profitable growth and cash generation.
About Privi Speciality Chemicals Limited
Privi Speciality Chemicals Limited (PRIVISCL) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.